here is the link for Nov additions and deletions
https://www.msci.com/eqb/gimi/smallcapdom/MSCI_Nov15_SC_IndiaDom_PublicList.pdf
Posts in category Value Pickr
Torrent Pharma Ltd (30-11-2015)
Kellton Tech – Fast growing IT guy in ISMAC space (30-11-2015)
a. 30 lac warrants (6.9% of equity) will be converted @90/- per unit as per the promoter -
http://www.moneycontrol.com/stocks/stock_market/corp_notices.php?autono=1221661
b. Plans to raise $15 million via QIP soon (in October-November 2015 timeframe as per following interview) -
http://www.moneycontrol.com/news/resultsboardroom/fy16-profit-growth-seen-10-11-weak-rupee-helping-kellton_2828981.html
$5 million for debt reduction and $10 mn for new acquisition.
TAKE SOLUTIONS LTD- will you take it? (30-11-2015)
The business of LS ( not SCM) definitely is attractive but the key here how the Company is going to be successful in extracting the outsourcing from the top pharma majors. Some more points
- On the strength of the considerable intelligence gathered, TAKE made the strategic decision of limiting its SCM activities to profitable segments while capitalizing on the growth potential of the LS industry and its USD 1.23 trillion Pharma & USD 289 billion Biotech markets.
- SCM from Rs 166 cr in 2009 to Rs 212 cr in 212 ( CAGR 5%) and LS from Rs 156 cr to Rs 475 cr in 2015 ( CAGR 20%). 20% is a very god sign.
- Life Sciences R&D spending is projected to grow 2.4 % per year from 2013 to 2020, reaching $162 billion.
- TAKE Solutions’ Clinical Accelerators to reduce the time taken to standardize clinical trial data by over 50% (when compared to standardization without the accelerators), thus reducing time to market.
- Experts joining LS vertical.
Source : Company AR
1. Depreciation is 30 yrs as Schedule II but I dont know the logic behind for 60 years. This is first time I am seeing a dep rate exceeding a rate as per Schedule II.
2. Ashish Dawan ( > 5% shareholder)has take an exit . he is from Chrysalis capital.
3. Working Capital requirement is huge and is consuming most of the operating CF. Further, CF is negative if you consider FA, Product Development and Goodwill.
4. They have intangible assets of Rs 100 cr and Rs 187 cr as Goodwill. Anyway, this can be ignored as it is accounting only. But on cashflow basis point no 3 is important.
Future potential is good provided we get improvement on 1) Cross Holdings 2) DSO 3) how they are going to tackle unattractive SCM 4) CF improvement from WC and Product development. FA and Goodwill, I am ignoring for the time being. 5)More details on how they are doing on acquisitions.
Rgds,
Possible disruption by Patanjali Yogapeeth (30-11-2015)
Here is another interesting article from Business today about how Patanjali is going about its business.
http://www.businesstoday.in/magazine/corporate/baba-ramdevs-patanjali-ayurved-forays-into-indias-rs-5300-crore-instant-noodles-market/story/226011.html
It mentions that Patanjali had turnover of Rs.1195 Cr in 2013-14 and Rs.2007 Cr in 2014-15 and they estimate their turnover to be Rs 5000 Cr in this financial year! The article claims that market cap of Patanjali would be around 40,000 Cr as per Wazir advisors when they touch sales of Rs 5000 Cr.! 
After reading the article, I feel that Patanjali would be much more disruptive that all of us have thought.
Tree house education and accessories ltd. – Potential candidate for improvement in RoE (30-11-2015)
The management finally speaks:
Possible disruption by Patanjali Yogapeeth (30-11-2015)
Here is an insightful article on Patanjali
Torrent Pharma Ltd (30-11-2015)
Looks like some re balancing in msci index. (could be small and midcap index re jig)
charts of maruti, ccl, cadila, torrent are similar with lots of volumes.
upticks with high vols in some textile stocks like indocount, welspun, himatsingka etc.
My Portfolio – Dhina (30-11-2015)
I have all the respect in the world for Sun Pharma and all that Mr Shangvi has achieved. However, simplistically, there are really 2 large issues on the table for Sun:
- the Ranbaxy merger and
- the Halol facility
As regards the former, of course there are challenges in making many of the Ranbaxy facilities USFDA compliant, but if anyone can do it, it is Shangvi - he has after all done 19 acquisitions for Sun thus far (India and outside India combined). It is also true that largely the acquisition has been reported to be quite synergistic by independent analysts.
The Halol facility is what is worrying analysts the most. For 2 reasons: firstly, its been a while since the issue was raised, and yet this has been hanging fire - not resolved satisfactorily by the company (if any industry expert has details as to exactly what are the issues that have been raised and what is the reported status on that, that would be wonderful). Secondly, I think the larger issue is the Indian pharma vs. USFDA per se.. And what I mean by this is: if big companies like Sun and Dr. Reddy - with all the expensive resources at their disposal (and with such high stakes), are facing such issues (some reported to be as basic as data availability and documentation), how easy are the resolution to such issues anyway? Ergo, is it possible that Indian pharma is so bad that they have been either been conjuring up data or not having any reliable data at all? Alternatively, is there any truth to the conspiracy theories that USFDA is gunning after Indian pharma (for reasons that need not be documented)?
Clarity on the above 2 items is quite essential before plunging onto Sun as an investment idea.
Best.
Is there any rule for max gain weekly, monthly and yearly basis? (30-11-2015)
I think tomorrow will clear the clouds...
if tomorrow cap is not revised..then it may go for correction...then its good time to accumulate..
Torrent Pharma Ltd (30-11-2015)
Why it is hammered today...is it sector rotation..I mean in to GST stocks..